Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
ILMN vs A
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
ILMN vs A — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $21.07B | $33.58B |
| Revenue (TTM) | $4.39B | $7.07B |
| Net Income (TTM) | $853M | $1.29B |
| Gross Margin | 67.1% | 38.8% |
| Operating Margin | 20.9% | 20.6% |
| Forward P/E | 26.8x | 19.9x |
| Total Debt | $2.55B | $3.35B |
| Cash & Equiv. | $1.42B | $1.79B |
ILMN vs A — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Illumina, Inc. (ILMN) | 100 | 39.3 | -60.7% |
| Agilent Technologie… (A) | 100 | 134.6 | +34.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ILMN vs A
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ILMN is the clearest fit if your priority is quality and momentum.
- 19.4% margin vs A's 18.3%
- +81.7% vs A's +11.3%
- 13.4% ROA vs A's 10.1%, ROIC 16.8% vs 13.5%
A carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 10 yrs, beta 1.23, yield 0.8%
- Rev growth 6.7%, EPS growth 3.2%, 3Y rev CAGR 0.5%
- 205.7% 10Y total return vs ILMN's 0.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.7% revenue growth vs ILMN's -0.8% | |
| Value | Lower P/E (19.9x vs 26.8x), PEG 1.35 vs 6.33 | |
| Quality / Margins | 19.4% margin vs A's 18.3% | |
| Stability / Safety | Beta 1.23 vs ILMN's 1.23, lower leverage | |
| Dividends | 0.8% yield; 10-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +81.7% vs A's +11.3% | |
| Efficiency (ROA) | 13.4% ROA vs A's 10.1%, ROIC 16.8% vs 13.5% |
ILMN vs A — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ILMN vs A — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ILMN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
A is the larger business by revenue, generating $7.1B annually — 1.6x ILMN's $4.4B. Profitability is closely matched — net margins range from 19.4% (ILMN) to 18.3% (A).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4.4B | $7.1B |
| EBITDAEarnings before interest/tax | $1.1B | $1.7B |
| Net IncomeAfter-tax profit | $853M | $1.3B |
| Free Cash FlowCash after capex | $989M | $993M |
| Gross MarginGross profit ÷ Revenue | +67.1% | +38.8% |
| Operating MarginEBIT ÷ Revenue | +20.9% | +20.6% |
| Net MarginNet income ÷ Revenue | +19.4% | +18.3% |
| FCF MarginFCF ÷ Revenue | +22.5% | +14.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.8% | +7.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.1% | -3.6% |
Valuation Metrics
A leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 25.5x trailing earnings, ILMN trades at a 2% valuation discount to A's 26.0x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.76x vs ILMN's 6.01x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $21.1B | $33.6B |
| Enterprise ValueMkt cap + debt − cash | $22.2B | $35.1B |
| Trailing P/EPrice ÷ TTM EPS | 25.45x | 25.96x |
| Forward P/EPrice ÷ next-FY EPS est. | 26.77x | 19.87x |
| PEG RatioP/E ÷ EPS growth rate | 6.01x | 1.76x |
| EV / EBITDAEnterprise value multiple | 19.58x | 19.89x |
| Price / SalesMarket cap ÷ Revenue | 4.86x | 4.83x |
| Price / BookPrice ÷ Book value/share | 7.95x | 5.00x |
| Price / FCFMarket cap ÷ FCF | 22.63x | 29.15x |
Profitability & Efficiency
ILMN leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $19 for A. A carries lower financial leverage with a 0.50x debt-to-equity ratio, signaling a more conservative balance sheet compared to ILMN's 0.94x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs A's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +32.8% | +18.7% |
| ROA (TTM)Return on assets | +13.4% | +10.1% |
| ROICReturn on invested capital | +16.8% | +13.5% |
| ROCEReturn on capital employed | +17.6% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.94x | 0.50x |
| Net DebtTotal debt minus cash | $1.1B | $1.6B |
| Cash & Equiv.Liquid assets | $1.4B | $1.8B |
| Total DebtShort + long-term debt | $2.6B | $3.4B |
| Interest CoverageEBIT ÷ Interest expense | 12.09x | 19.53x |
Total Returns (Dividends Reinvested)
A leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in A five years ago would be worth $9,203 today (with dividends reinvested), compared to $3,717 for ILMN. Over the past 12 months, ILMN leads with a +81.7% total return vs A's +11.3%. The 3-year compound annual growth rate (CAGR) favors A at -2.8% vs ILMN's -10.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +3.2% | -13.6% |
| 1-Year ReturnPast 12 months | +81.7% | +11.3% |
| 3-Year ReturnCumulative with dividends | -27.1% | -8.2% |
| 5-Year ReturnCumulative with dividends | -62.8% | -8.0% |
| 10-Year ReturnCumulative with dividends | +0.7% | +205.7% |
| CAGR (3Y)Annualised 3-year return | -10.0% | -2.8% |
Risk & Volatility
Evenly matched — ILMN and A each lead in 1 of 2 comparable metrics.
Risk & Volatility
A is the less volatile stock with a 1.23 beta — it tends to amplify market swings less than ILMN's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ILMN currently trades 89.2% from its 52-week high vs A's 74.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.23x | 1.23x |
| 52-Week HighHighest price in past year | $155.53 | $160.27 |
| 52-Week LowLowest price in past year | $73.86 | $104.79 |
| % of 52W HighCurrent price vs 52-week peak | +89.2% | +74.0% |
| RSI (14)Momentum oscillator 0–100 | 65.2 | 52.5 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 2.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ILMN as "Buy" and A as "Buy". Consensus price targets imply 39.9% upside for A (target: $166) vs 6.3% for ILMN (target: $147). A is the only dividend payer here at 0.84% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $147.38 | $166.00 |
| # AnalystsCovering analysts | 50 | 38 |
| Dividend YieldAnnual dividend ÷ price | — | +0.8% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $0.99 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.5% | +1.3% |
ILMN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). A leads in 2 (Valuation Metrics, Total Returns). 1 tied.
ILMN vs A: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is ILMN or A a better buy right now?
For growth investors, Agilent Technologies, Inc.
(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (26. 8x forward), making it the more compelling value choice. Analysts rate Illumina, Inc. (ILMN) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ILMN or A?
On trailing P/E, Illumina, Inc.
(ILMN) is the cheapest at 25. 5x versus Agilent Technologies, Inc. at 26. 0x. On forward P/E, Agilent Technologies, Inc. is actually cheaper at 19. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 35x versus Illumina, Inc. 's 6. 33x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — ILMN or A?
Over the past 5 years, Agilent Technologies, Inc.
(A) delivered a total return of -8. 0%, compared to -62. 8% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: A returned +205. 7% versus ILMN's +0. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ILMN or A?
By beta (market sensitivity over 5 years), Agilent Technologies, Inc.
(A) is the lower-risk stock at 1. 23β versus Illumina, Inc. 's 1. 23β — meaning ILMN is approximately 0% more volatile than A relative to the S&P 500. On balance sheet safety, Agilent Technologies, Inc. (A) carries a lower debt/equity ratio of 50% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ILMN or A?
By revenue growth (latest reported year), Agilent Technologies, Inc.
(A) is pulling ahead at 6. 7% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 3. 2% for Agilent Technologies, Inc.. Over a 3-year CAGR, A leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ILMN or A?
Illumina, Inc.
(ILMN) is the more profitable company, earning 19. 6% net margin versus 18. 8% for Agilent Technologies, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus 19. 9% for ILMN. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ILMN or A more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 35x versus Illumina, Inc. 's 6. 33x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Agilent Technologies, Inc. (A) trades at 19. 9x forward P/E versus 26. 8x for Illumina, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for A: 39. 9% to $166. 00.
08Which pays a better dividend — ILMN or A?
In this comparison, A (0.
8% yield) pays a dividend. ILMN does not pay a meaningful dividend and should not be held primarily for income.
09Is ILMN or A better for a retirement portfolio?
For long-horizon retirement investors, Agilent Technologies, Inc.
(A) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23), 0. 8% yield, +205. 7% 10Y return). Both have compounded well over 10 years (A: +205. 7%, ILMN: +0. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ILMN and A?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
A pays a dividend while ILMN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.